Evidence map›Paper›PMID 35223137›Full record

ArticleACS catalysis2021

Structural and substrate specificity analysis of 3-

Rylee Wander, Andrea M Kaminski, Zhangjie Wang, Eduardo Stancanelli, Yongmei Xu, Vijayakanth Pagadala, Jine Li, Juno M Krahn, Truong Quang Pham, Jian Liu and 1 more

Open access · greenAbstract read
In one paragraph

Article in ACS catalysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Emerging chemical and biochemical tools for studying 3-American journal of physiology. Cell physiology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Rylee WanderDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.
Andrea M KaminskiGenome Integrity and Structural Biology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina, USA.
Zhangjie WangDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.
Eduardo StancanelliDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.
Yongmei XuDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.
Vijayakanth PagadalaGlycan Therapeutics Corp, 617 Hutton Street, Raleigh, North Carolina, USA.
Jine LiDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.
Juno M KrahnGenome Integrity and Structural Biology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina, USA.
Truong Quang PhamGlycan Therapeutics Corp, 617 Hutton Street, Raleigh, North Carolina, USA.
Jian LiuDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.
Lars C PedersenGenome Integrity and Structural Biology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina, USA.
University of North Carolina at Chapel Hill · USNational Institutes of Health · US

Funding

Crystallographic studies of macromolecular structuresZIAES102645 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI PEDERSEN, LARS · 2009 to 2017
$9.4M
In vitro synthesis of recombinant heparan sulfateR01HL094463 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LIU, JIAN, PAWLINSKI, RAFAL L · 2009 to 2021
$5.2M
Diverse Heparan Sulfate Oligosaccharide Libraries For Understanding and Therapeutically Manipulating GlycosaminoglycansR44GM134738 · NIGMS · GLYCAN THERAPEUTICS CORPORATION · PI PAGADALA, VIJAYAKANTH · 2019 to 2021
$3.2M
Reactor for Insect Cell CultureR42GM128484 · NIGMS · GLYCAN THERAPEUTICS CORPORATION · PI XU, YONGMEI · 2018 to 2020
$1.9M
Synthesis and Pharmacological Evaluation of Homogenous Ultra-Low Molecular Weight HeparinsR01HL144970 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LIU, JIAN · 2019 to 2021
$946k
Developing Heparan Sulfate Glycan ArrayR41GM123792 · NIGMS · GLYCAN THERAPEUTICS CORPORATION · PI LIU, JIAN · 2017 to 2018
$297k
Development of a New Carbohydrate-based Anticoagulant DrugR41HL139187 · NHLBI · GLYCAN THERAPEUTICS CORPORATION · PI LIU, JIAN · 2017 to 2017
$225k
Intramural NIH HHS ZIA ES102645NHLBI NIH HHS R01 HL094463NHLBI NIH HHS R01 HL144970NHLBI NIH HHS R41 HL139187NIGMS NIH HHS R41 GM123792NIGMS NIH HHS R42 GM128484NIGMS NIH HHS R44 GM134738
6 · The paper itself

Abstract

Heparan sulfate 3-

Indexed as

chemoenzymatic synthesisheparan sulfate biosynthesisoligosaccharideprotein/substrate complexSulfotransferase

Identifiers

PMID35223137
PMCPMC8865405
OpenAlexW3217092201

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.